"In the olaparib LT group 244 genetic alterations were detected with TP53 BRCA1 and BRCA2 mutations being most common (90% 25% and 35% respectively). BRCA2 mutations were enriched among the LT responders. BRCA methylation was not associated with response duration. High myriad HRD score (>42) and/or BRCA1/2 mutation was associated with LT response to olaparib"xsd:string